MedTrace Logo

Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia.

NCT04312555 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-20

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy of Alprostadil (Prostaglandin E2) as adjuvant therapy after failure of direct but indirect angiosomal revascularization in patients with critical limb ischemia.

Conditions

  • Critical Limb Ischemia

Interventions

DRUG

Alprostadil

Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ashraf Elnaggar, Dr · Assiut University

  • Hassan Bakr El-Badawy, Prof · Assiut University

  • Mohamed Elsagheer Elhewwy, Prof · Al-Azhar University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-04-01
Completion
2021-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312555 on ClinicalTrials.gov